Kairasec (Candesartan Cilexetil)

After oral administration, candesartan cilexetil is converted to candesartan, which selectively blocks angiotensin II type 1 receptors. This inhibition prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation, resulting in relaxed blood vessels, reduced fluid retention, and lower arterial pressure.

The appropriate dose of Kairasec is individualized by the prescribing healthcare professional based on the patient’s blood pressure, renal function, concomitant medications, and clinical response. No fixed dosing regimen is provided here; the prescriber will select the strength and titration schedule that best fits the patient’s needs.

Safety data for candesartan during pregnancy and lactation are limited, and the drug is generally avoided because of potential risk to the fetus. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Kairasec, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and import documentation.

Kairasec (candesartan) is an ARB that offers once‑daily dosing, a favorable side‑effect profile, and effective blood‑pressure reduction comparable to other ARBs such as losartan or valsartan. Unlike ACE inhibitors, candesartan does not cause a persistent cough and has a lower incidence of angioedema, making it a suitable alternative for patients intolerant to ACE inhibitors.

Kairasec tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Kairasec is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and not alter the schedule without medical advice.

Serious adverse events linked to candesartan include angioedema (rapid swelling of the face, lips, tongue or throat), severe hypotension, hyperkalemia (elevated potassium levels), and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, dizziness, fainting, or significant changes in urine output.

Kairasec should be avoided in patients with known hypersensitivity to candesartan or any component of the formulation, in those with severe hepatic impairment, and in individuals with conditions that predispose to high potassium levels unless closely monitored. It is also contraindicated in patients taking aliskiren together with an ARB if they have diabetes.